NEW YORK, April 6, 2026. The S&P 500 opened at 6,587.66 on Monday, April 6, 2026, extending the prior week’s 3.4% rebound as geopolitical relief and corporate deal news drove early price action. Soleno Therapeutics (SLNO) was the standout mover, surging over 33% after Neurocrine Biosciences (NBIX) unveiled a $2.9 billion cash acquisition at $53.00 per share — a 51% premium to SLNO’s 30-day volume-weighted average price. Netflix (NFLX) added approximately 1.3%–3.25% following a Goldman Sachs upgrade to Buy with a $120 price target, as analyst Eric Sheridan argued the streaming giant offers the most attractive risk/reward in large-cap media ahead of its April 16 earnings. The session opened with the market absorbing four days of accumulated data and geopolitical signal: March NFP’s +178,000 blockbuster beat from Good Friday, the Iran-Oman Hormuz transit protocol announced Thursday, and the quiet expiry of Trump’s April 6 Hormuz deadline. ISM Services PMI for March, released Monday at 10 AM ET, delivered a complex reading — a headline miss at 54.0 versus 55.4 consensus, but a Prices Paid component of 70.7 that is the highest since October 2022 and the largest one-month jump in 13 years. Monday’s open belongs to the deal flow and the data, but the Iran backdrop defines the macro context for everything.
The macro setup — what Monday’s open inherited from four days of silence
Monday’s 9:30 AM ET bell was the first equity market open since Thursday April 2’s 1 PM close — the longest gap between sessions of the entire Iran conflict period. In those four days, the market accumulated without release: a March NFP print of +178,000 that tripled the +57,000 consensus; an ISM Services PMI with a Prices Paid component that surged 7.7 points to 70.7; the Iran-Oman Hormuz transit governance protocol unveiled Thursday; Trump’s “2–3 weeks more” strike timeline from his Wednesday night national address; and the quiet, unacknowledged expiry of the April 6 Hormuz deadline Trump had originally set in late March. The pre-market futures session — which had been the only available pressure valve through the long weekend — showed the S&P 500 up modestly at the open, consistent with the market’s decision to price the NFP beat as a modest positive without fully incorporating the inflation signal in the ISM Prices Paid component.
The prior week’s 3.4% S&P 500 rebound — the strongest weekly gain since early in the conflict — reflected two developments that defined market sentiment heading into the Easter weekend: the Wall Street Journal’s reporting that Trump was open to ending the war without requiring Hormuz reopening as an explicit ceasefire condition, and the Iran president’s signal of willingness to negotiate. The Monday open tests whether those signals were durable or whether the Iran-Oman protocol’s governance implications — which effectively institutionalise Iranian oversight of the strait even after any ceasefire — will be priced as a structural energy cost premium that limits the S&P’s recovery upside. Pre-market futures heading into the bell suggested the market’s initial verdict: modest gains, selective sector rotation, and no single directional conviction that resolves the war’s ambiguity in either direction.
SLNO +33%: Neurocrine’s $2.9B all-cash bid for Soleno Therapeutics — the VYKAT XR thesis
Neurocrine Biosciences (Nasdaq: NBIX) announced a definitive agreement to acquire Soleno Therapeutics (Nasdaq: SLNO) for $53.00 per share in cash — a total transaction equity value of $2.9 billion — before Monday’s open. Soleno shares surged more than 33% in premarket trading to approximately $52.52, converging tightly on the deal price as merger arbitrageurs established the standard spread trade. The deal is fully financed from Neurocrine’s cash on hand plus a modest amount of pre-payable debt. There is no financing condition. Both boards of directors approved the transaction unanimously. The acquisition is expected to close within 90 days, subject to customary regulatory review.
The deal centres on VYKAT XR (diazoxide choline) — Soleno’s sole commercial product and the first drug ever approved by the FDA to treat hyperphagia, the defining clinical feature of Prader-Willi syndrome (PWS). Prader-Willi is a rare genetic neurodevelopmental disorder affecting approximately one in every 15,000 live births — roughly 10,000 people in the United States. Its hallmark symptom is relentless, life-threatening hunger that compels affected patients to eat to the point of obesity, diabetes, or fatal complications including stomach rupture. VYKAT XR received FDA approval in Q2 2025 and launched immediately to strong early adoption: the drug generated $190 million in full-year 2025 revenue, including a Q4 2025 run rate of $92 million — an annualised pace above $360 million in its first year of commercial availability. For context, Neurocrine’s flagship drug Ingrezza — approved for involuntary muscle movements and the anchor of its current portfolio — generated $2.51 billion in revenue in 2025. VYKAT XR, at its current launch trajectory, has the characteristics of a second blockbuster-scale product for a company that has not had one since Ingrezza’s approval.
Neurocrine CEO Kyle Gano described the deal’s commercial rationale precisely: the acquisition will leverage Neurocrine’s “experience and capabilities to expand VYKAT XR’s reach to benefit more patients.” The specific commercial synergy is Neurocrine’s existing salesforce in pediatric endocrinology — the same physician specialties that prescribe and manage Prader-Willi syndrome. RBC Capital Markets described the deal as making “very reasonable strategic sense,” noting that Neurocrine “could potentially find synergies between its expanded salesforce and SLNO’s current capabilities.” BMO Capital Markets analyst Evan Seigerman called it “a more sensible way into metabolic disease” than Neurocrine’s own preclinical obesity candidates, which face significant competitive and regulatory hurdles in a field that GLP-1 drugs now dominate. The $2.9 billion price tag — at roughly 8x VYKAT XR’s annualised Q4 run rate — is a premium that reflects both the drug’s first-in-class status for an unmet need and the optionality of expanding the PWS indication to broader hyperphagia applications. Stifel analysts described themselves as “admittedly surprised SLNO sold at this price” given VYKAT XR’s strong launch momentum, suggesting the market may have been willing to price the company higher on a standalone basis.
Netflix +3.25%: Goldman’s Buy upgrade and the three-part thesis for NFLX ahead of April 16 earnings
Goldman Sachs analyst Eric Sheridan upgraded Netflix (Nasdaq: NFLX) to Buy from Neutral on Monday morning, raising the 12-month price target from $100 to $120 — implying approximately 26% upside from the stock’s pre-upgrade trading price near $95–98. Netflix shares rallied approximately 3.25% in premarket trading on the news. The upgrade ends months of Goldman’s neutral stance on the dominant streaming company — a position Sheridan had maintained through several quarters of execution concerns tied primarily to Netflix’s ultimately abandoned pursuit of Warner Bros. Discovery assets. Goldman’s shift to Buy is built on three distinct arguments that are each worth understanding independently.
Valuation re-entry after the WBD deal collapse. Netflix walked away from discussions to acquire Warner Bros. Discovery assets, subsequently collecting a $2.8 billion merger termination fee from Paramount Skydance Corporation. Goldman describes this as returning Netflix to a “standalone execution story” with scope for positive estimate revisions. The stock currently trades at a price/earnings-to-growth (PEG) ratio of approximately 1.1 times — well below its five-year historical average of approximately 1.65 times. Goldman views that gap, combined with an 18% stock decline over the prior six months driven partly by WBD deal overhang, as the entry point that warranted the upgrade.
Revenue acceleration from price hikes and advertising. Netflix raised prices across its U.S. subscription tiers in March 2026 — the second increase in 15 months. The Standard ad-free tier increased $2 to $19.99; Premium went up $2 to $26.99; the ad-supported tier rose $1 to $8.99. Goldman calculates these adjustments could generate a combined $3 billion in incremental revenue through 2026 and 2027. Needham projects approximately $1.7 billion in incremental revenue and roughly 300 basis points of North America growth for fiscal 2026 from the hike alone. More structurally, Goldman forecasts Netflix’s advertising revenue growing from approximately $1.5 billion in 2025 to $4.5 billion by 2027 and approaching $9.5 billion annually by 2030 — a ~6x increase in five years. The ad-supported tier’s traction with advertisers, validated by channel checks at New York NewFronts events, provides the growth runway to support that projection.
Capital return acceleration post-M&A abandonment. With the WBD pursuit ended and $11 billion in guided 2026 free cash flow that Goldman describes as potentially conservative, Netflix is positioned to resume aggressive share buybacks. Goldman projects Netflix could repurchase 20–25% of its current market capitalisation over the next five years — a pace that would meaningfully reduce the share count and support per-share earnings growth independent of revenue acceleration. Netflix reports Q1 2026 earnings on April 16, ten days from Monday’s open. Goldman is explicitly positioning ahead of that print, betting subscriber stability despite price hikes, accelerating ad revenue, and cleaner management guidance will validate the upgrade. Netflix’s April 16 report is the first major earnings catalyst of the season for large-cap consumer technology.
ISM Services PMI 54.0 — the headline miss that hides a historic inflation surge
The March ISM Services PMI printed Monday at 10:00 AM ET — the data point that was scheduled for Good Friday but absorbed into Monday’s session alongside everything else. The headline: 54.0, down from 56.1 in February and below the 55.4 consensus. On its face, a modest miss — the service sector’s 21st consecutive month of expansion, corresponding to a 1.9% annualised real GDP growth rate per ISM’s own methodology, and the second-highest reading since October 2024. The headline is not the story. The story is the Prices Paid sub-index: 70.7, up 7.7 points from February’s already-elevated 63.0. That is the highest Prices Paid reading since October 2022, the 16th consecutive month above 60, and — most critically — the largest single-month jump in more than 13 years. The last time prices paid in the services sector accelerated this sharply in a single month was in the post-Hurricane Katrina supply disruption period of 2012–2013.
The Iran war’s fingerprints are explicit throughout the ISM survey’s respondent commentary, which ISM Chair Steve Miller described as being dominated by “impacts and adjustments due to the conflict with Iran.” Companies across multiple industries reported higher gas and diesel pricing. Wholesalers described “threats to close the Strait of Hormuz and rising war-risk surcharges” pressuring landed costs. Mining sector respondents noted “political uncertainty with Iran conflict has resulted in less international business.” Real estate and leasing companies flagged that “the war in Iran has added an additional layer of uncertainty on top of an already shaky macroeconomic climate.” Eleven industries reported higher inventories — the highest count in months — with most citing precautionary stockpiling against anticipated supply chain disruptions. The Services Employment Index collapsed from 51.8 to 45.2, a 6.6-point drop that Bloomberg characterised as “one of the biggest monthly declines since the pandemic.” The ISM Employment reading contradicts Friday’s NFP +178,000, but as Brean Capital’s John Ryding noted: “The drop in employment would be more worrisome had we not already had payrolls for March.” The more concerning component remains Prices Paid. Ryding added: “ISM prices paid is a very useful indicator of trends in inflation and this reading should be disconcerting to the Fed and is consistent with inflation running close to 4%.” For the Federal Reserve, the combination of a +178K NFP (no emergency cut justification) and a 70.7 Prices Paid reading (no rate cut justification) cements the hold posture through at least the April 28–29 FOMC meeting.
The Iran backdrop — ceasefire diplomacy, the Hormuz protocol, and the expired deadline
Monday April 6 is the 37th day of Operation Epic Fury and the day Trump’s original Hormuz reopening deadline was supposed to expire — quietly, without acknowledgement in his Wednesday night national address and without any action from either side that formally marks its passage. The geopolitical context for Monday’s equity session is more diplomatically active than any prior week of the conflict: the Wall Street Journal reported over the Easter weekend that Trump is open to ending the war without Hormuz reopening as an explicit ceasefire condition, a significant softening of the public U.S. position. Iran’s president signalled willingness to negotiate. The Iran-Oman bilateral Hormuz transit protocol — announced Thursday and not yet priced by equity markets through the Good Friday closure — remains the most structurally consequential geopolitical development of the conflict period for long-term energy pricing.
Brent crude opened Monday modestly lower as the ceasefire diplomatic momentum provided marginal relief to the war premium. But the physical market reality — five vessels per day transiting Hormuz versus a pre-war average of 138 — has not changed over the Easter weekend, and the Strategic Petroleum Reserve buffer that prevented the full physical supply shock from transmitting into consumer prices is entering the window analysts had previously identified as the exhaustion point: early-to-mid April. That exhaustion dynamic, combined with the ISM Prices Paid reading of 70.7, creates the specific stagflationary signal that the Federal Reserve is most constrained to address: an economy with a surprisingly strong labour market, cooling but still-expanding services activity, and input cost inflation accelerating at the fastest pace in 13 years. There is no rate policy tool that addresses a supply-side oil shock without creating collateral damage to employment or growth. The VIX remaining above 25 is the market’s honest answer to that policy constraint: uncertainty is structurally elevated and unlikely to resolve until Hormuz throughput recovers toward pre-war levels.
NFP +178,000 — how the Good Friday blockbuster is landing in Monday’s session
The March Non-Farm Payrolls print of +178,000 — released Good Friday into closed equity markets — is the most important single economic data point landing into Monday’s open. The number tripled consensus (+57,000), with private service-providing payrolls accounting for 143,000 of the total gain — confirming that the February disaster (–92,000) was primarily a one-time event driven by the Kaiser Permanente healthcare worker strike resolution. Healthcare payrolls rebounded sharply as approximately 30,000 nurses returned to work following the California and Hawaii strike resolution in late February. Unemployment rate and average hourly earnings data confirmed the no-emergency-cut posture: the labour market is not deteriorating at the pace that would force the Fed’s hand before seeing more data on how the Iran war’s inflation transmits through Q2.
The market’s reaction to the +178,000 print — a modest positive open rather than a sharp rally — reflects exactly what was expected: a labour market that is stronger than feared is good news for growth expectations, but in the context of a 70.7 Prices Paid reading and Brent crude above $100, “stronger labour market” also means “less scope for rate cuts” and “more inflation pipeline.” The equities market is pricing the NFP beat as a floor for growth expectations while simultaneously pricing the ISM Prices Paid as a ceiling for P/E multiple expansion — the specific combination that defines a stagflationary equity environment. Both data points are simultaneously true, and Monday’s modest open is the market’s honest assessment that the combination does not resolve cleanly in either the bull or the bear direction. For context on how labour market data like Monday’s feeds through to equity market positioning, PreMarket Daily’s pre-market framework provides relevant analytical context.
The week ahead from Monday’s open — DAL earnings, March CPI, and FOMC minutes
The week of April 6 is the first full five-session trading week since the Iran war began, and it arrives with a calendar that matches the data density of the prior week. Delta Air Lines (DAL) reports on Thursday with a consensus EPS of approximately $0.64 — the first major airline earnings of the conflict period and the clearest read-through on how the energy cost shock is transmitting into transportation sector margins and forward guidance. March CPI lands on Friday, the first major inflation print that fully incorporates the Iran war’s energy channel: February CPI was measured before the Hormuz closure’s full gasoline price impact worked through the pump price series. If the 70.7 ISM Prices Paid reading is an accurate leading indicator — and historically it has been — the March CPI will show a meaningful step-up in both headline and energy-driven components. The FOMC minutes from the March meeting also release this week, providing the most recent official record of how Fed officials were thinking about the balance between inflation and growth risks before the NFP beat and ISM Prices Paid surge gave the policy dilemma its current, sharpest form.
Monday’s SLNO and NFLX moves, the ISM data, and the accumulated Good Friday data are the opening chapter of what is likely the most analytically dense week of earnings and economic data since the Iran war began on February 28. The PreMarket Daily daily trading plan covers each session’s key data, earnings, and positioning before the open. Treasury yields and the dollar will be the first movers to price Friday’s CPI as the week develops — and their reaction will determine whether Monday’s relatively stable opening equilibrium holds through the week or gives way to a more volatile repricing of the stagflation risk that the ISM data has just made explicit.
This article is published by PreMarket Daily for informational and educational purposes only. Nothing here constitutes financial advice, investment recommendations, or an offer to buy or sell any securities. Always consult a qualified financial professional before making investment decisions.
Other Articles
